United States: Practical Implications From Amarin

Amarin is an important US district court opinion affirming the importance of the Second Circuit's Caronia decision and finding that pharmaceutical and medical device companies have a constitutionally protected right to provide truthful and non-misleading information regarding off-label uses of their products.

The US District Court for the Southern District of New York ruled against the Food and Drug Administration (FDA) and upheld the rights of a pharmaceutical manufacturer to make truthful and non-misleading statements regarding off-label uses of its FDA-approved drug, including the right to affirmatively make those statements through sales representatives to healthcare providers, following the US Court of Appeals for the Second Circuit's landmark opinion in United States v. Caronia.1

The court held that plaintiff drug manufacturer Amarin Pharma Inc. (Amarin) may make truthful and non-misleading statements to doctors regarding off-label uses of its FDA-approved drug Vascepa and that such speech may not form the basis of a prosecution for misbranding. Relying heavily on Caronia, US District Judge Paul A. Engelmayer granted Amarin's motion for preliminary relief against the FDA, stating that, without relief, Amarin's "First Amendment rights [would] be chilled by the threat of a misbranding action."2

COURT REJECTS FDA'S READING OF CARONIA

In Amarin, FDA argued strongly for its interpretation of Caronia, asserting that FDA is able to bring a misbranding action against a manufacturer or its representative where the conduct at issue consists solely of truthful and non-misleading speech promoting an off-label use of an approved drug.3 The court squarely rejected that interpretation: "The [c]ourt's considered and firm view is that, under Caronia¸ the FDA may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment."4 FDA also argued that the Caronia decision was limited to the facts of that particular case,5 but the court similarly rejected that argument.6 This important decision further solidifies the free speech protections afforded to drug manufacturers that wish to provide truthful and non-misleading information to doctors about their drugs for off-label uses, particularly in light of contemporary First Amendment law, which has developed and is set forth in Central Hudson Gas and Electric Corp. v. Public Service Communication of New York, 447 U.S. 557 (1980).

AMARIN CITES STUDIES AND THE FDA'S COMPLETE RESPONSE LETTER TO SUPPORT ITS OFF-LABEL USE

Amarin manufactures Vascepa, a pure eicosapentaenoic omega-3 fatty-acid drug currently approved by FDA to reduce triglyceride levels in adult patients with very high triglycerides. Physicians also widely, and lawfully, prescribe Vascepa for patients with "persistently" high triglycerides. To support a requested label change, Amarin conducted a study, called ANCHOR, to evaluate Vascepa for patients with persistently high triglyceride levels who were already on statin therapy.7 The ANCHOR study showed that Vascepa produced a statistically significant decrease in triglyceride levels in persons with persistently high triglycerides. Amarin sought a new indication based on the ANCHOR study results, but in an April 27, 2015 Complete Response Letter, FDA refused approval for the new indication and rejected Amarin's request to incorporate ANCHOR data into Vascepa's labeling. FDA's letter stated that Vascepa "may be considered to be misbranded under the [Federal Food, Drug, and Cosmetic Act (FDCA)] if it is marketed with this change before approval of this supplemental application."8

Amarin sought relief from potential prosecution for use of general and specific statements about the results of the ANCHOR study. After its complaint, Janet Woodcock, director of FDA's Center for Drug and Evaluation and Research, issued a letter setting out FDA's position on Amarin's proposed statements. In that letter, FDA made important concessions about certain communications, noting that many already fell within existing FDA guidance for distribution of reprints. Although the FDA letter sought to moot the dispute altogether, Amarin rejected some of FDA's proposed additional restrictions and conditions. By issuing the letter to the court and noting approaches to make the communications non-misleading (e.g., use of disclaimers), FDA provided industry with a roadmap to construct non-misleading speech. Nevertheless, the court deemed the case ripe because Amarin faced a "non-extinguished threat of a misbranding prosecution."9

COURT TO FDA: YOU'RE CHILLING AMARIN'S RIGHT TO DISCUSS THE TRUTHFUL SCIENCE ON ITS PRODUCT

In opposing Amarin's request for an injunction, FDA raised three primary arguments, all of which were rejected. First, it argued that Amarin's suit was a "frontal assault . . . on the framework for new drug approval that Congress created in 1962." The court dismissed this concern, holding that the FDCA statute from 1962 must be considered in light of more recent First Amendment law that protects truthful and non-misleading commercial speech. Second, the court argued that only certain truthful and not-misleading statements could be protected. The court rejected this argument on the basis that the Caronia holding applied across the board to all truthful and not-misleading speech and that Caronia specifically reached proactive oral statements by a drug manufacturer's sales representatives. Third, FDA argued that it could use truthful and non-misleading statements to establish intent to promote off-label uses. The court declined to consider that argument as "beside the point," writing "Amarin's lawsuit is directed instead to the act requirement—the situation in which a misbranding action takes aim at truthful, non-misleading speech. And Caronia construed the misbranding statute, categorically, not to reach a manufacturer or its representative under those circumstances."10

To be clear, neither Caronia nor Amarin foreclose the potential for prosecutions related to off-label marketing. The court explicitly addressed two important limitations on Caronia that remain unchanged. First, that "the First Amendment does not protect false or misleading commercial speech." And, second, that "the First Amendment protects expression, not conduct." On this second limitation, the court further wrote "[a] manufacturer that engages in non-communicative activities to promote off-label use cannot use the First Amendment as a shield. Caronia holds protected, and outside the reach of the FDCA's misbranding provisions, off-label promotion only where it wholly consists of truthful and non-misleading speech."11

PRACTICAL IMPLICATIONS

Amarin marks an important development post-Caronia and serves as an important affirmation of the right to truthful and non-misleading statements made to promote pharmaceuticals. This decision, if upheld, will cause pharmaceutical and medical device companies to reconsider the scope of promotion distributed for their products. Because the FDA still can take enforcement action against a company for off-label promotion that is inaccurate or misleading, if a company decides to rely on the decision before any potential appeal is resolved, it is critical for the company to ensure that the off-label communications are truthful and non-misleading.

Examples of Protected Activities

  • Sales representatives and others (medical science liaisons, nurse educators, and other field personnel) can initiate discussions and "promote" off-label uses of drugs through truthful and non-misleading statements, which contain adequate disclaimers.
  • Speech covered by this right can be either oral or written and in the form of articles, reprints, guidelines, or other truthful, scientifically accurate, and non-misleading statements.
  • Reprints and other information do not necessarily need to be on a specific product at issue, because the court agreed that articles on the effect of eicosapentaenoic and docosahexaenoic omega-3 fatty acids, the active ingredients in Vascepa, could be distributed.
  • Companies can summarize articles or use other formats as long as the summary is accurate and factual and not misleading (including through material omission).
  • Truthful and non-misleading speech is protected, and the venue is not a decisive factor—however, the government may consider the circumstances surrounding a communication to determine if there is noncommunicative conduct that should be evaluated in considering potential misbranding arguments.
  • Importantly, if the speech is considered promotion and is written, it will need to be submitted to FDA in a signed form 2253 consistent with 21 CFR 314.81(b)(3)(i).
  • As the court noted, companies can seek FDA views on whether the off-label use speech is misleading through FDA's current prelaunch and advisory comments processes; obviously, that will be a strategic decision for each company and may require companies to create decision tree standard operating procedures for when FDA review is requested.

Examples of Activities That Are Outside the Scope of Amarin

  • False or misleading speech that can arise from inaccuracies, inappropriate bias, omissions of material information, dated information, or absence of disclaimers.
  • Knowing and willful noncommunicative activities intended to improperly induce off-label use, such as activities ordinarily subject to the Medicare Anti-Kickback Statute.

Footnotes

[1] Amarin Pharma, Inc. v. United States Food & Drug Administration, et al., No. 1:15-cv-03588 PAE, slip op. at 45 (S.D.N.Y. Aug. 7, 2015).

[2] Id. at 66.

[3] Id. at 18.

[4] Id. at 45.

[5] Id. at 44.

[6] Id. at 48. "This [c]ourt therefore rejects the FDA's reading of Caronia as a mere artifact of that case's particular facts and circumstances." The court further noted, in several places, that the appropriate forum for FDA disagreement with Caronia would have been a petition for rehearing or certiorari, but not this case. See, e.g., p. 50 n. 57.

[7] Id. at 21–23.

[8] Id. at 26.

[9] Id. at 42.

[10] See id. at 49-51.

[11] Id. at 52.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions